Advanced Imaging Using PET and MRI to Predict Progression in Pulmonary Fibrosis Phase 2 Study of Combined Imaging in Non-IPF Interstitial Lung Disease

What this Trial Is About

Researchers are studying people with non-idiopathic pulmonary fibrosis interstitial lung disease non-IPF ILD to see if special imaging tests can predict how quickly their lung disease will get worse. The study focuses on measuring collagen buildup and tissue damage in the lungs using two imaging methods 68GaCBP8 positron emission tomography PET and dynamic contrast-enhanced magnetic resonance imaging DCE-MRI. The goal is to identify which patients will develop progressive pulmonary fibrosis over time. The study involves 60 participants who are on stable immunosuppressive medication. Each participant will receive a single intravenous injection of 68GaCBP8 and gadoterate meglumine during imaging. They will undergo combined PET and DCE-MRI scans at the start of the study. Researchers will compare the results of these scans to see if they can better predict disease progression when combined versus each alone. Participants will be followed for up to 24 months, with researchers monitoring lung function through pulmonary function tests and high-resolution CT scans, as well as respiratory symptoms. The main measurement is development of progressive pulmonary fibrosis. Secondary measures include declines in lung capacity tests. This study aims to improve understanding of disease progression using advanced imaging techniques.

Advanced Imaging for Pulmonary Fibrosis